Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Surovatamig · AZD-0486, TNB-486

Bispecific antibody · Immune activation, directed at CD3 (CD3E) and CD19 · developed by ASTRAZENECA

Phase 3 Most advanced trial
AZN Developer

What is Surovatamig?

Surovatamig is a fully human bispecific IgG4 T-cell engager antibody that binds CD3 on cytotoxic T lymphocytes and CD19 on B cells. By bridging the two, it redirects T cells to CD19-expressing cells, and it is being studied in large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD-0486, TNB-486
Drug type
Bispecific antibody
Targets
CD3 (CD3E), CD19
Mechanism
Immune activation, directed at CD3 (CD3E) and CD19
Pathways
CTL-mediated killing of tumor cells
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
3QW12I37H1

Conditions studied

Large B-cell Lymphoma

Other drugs acting on CD3E / CD19

More from ASTRAZENECA

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Surovatamig

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.